IP Library Granted Patent US 7,144,869
Granted Patent B2
US 7,144,869 · App. 10/310,398 · Granted Dec 5, 2006

Nucleic acid injected into hapatic vein lumen and delivered to primate liver

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,144,869
App. No.
10/310,398
Granted
Dec 5, 2006
Kind
B2
Abstract

Processes are described for obtaining high levels of gene expression in primates after injection of nucleic acid to the liver via the lumen of the hepatic vein. The described process results in high level of gene expression with transient increases in liver enzymes.

Claims (17)

1. A process for delivering a polynucleotide to a primate liver cell, comprising:

a) transiently occluding afferent and efferent blood vessels of the liver in a primate; and,

b) injecting the polynucleotide in a solution into the lumen of a hepatic vessel wherein the injection of the solution results in portal vein pressure of 10 mm Hg or greater.

2. The process of claim 1 wherein the solution is injected at a rate of 18 ml/kg/min or greater.

3. The process of claim 1 wherein the solution is injected at a rate of 36 ml/kg/min or greater.

4. The process of claim 1 wherein the solution is injected at a rate of 48 ml/kg/min or greater.

5. The process of claim 1 wherein the injection of the solution results in portal vein pressure of 45 mm Hg or greater.

6. The process of claim 1 wherein the injection of the solution results in portal vein pressure of 105 mm Hg or greater.

7. The process of claim 1 wherein the polynucleotide consists of naked DNA.

8. The process of claim 1 wherein the polynucleotide is selected from the group consisting of a viral vector and a non-viral vector.

9. The process of claim 1 wherein the polynucleotide consists of a blocking polynucleotide for preventing gene expression.

10. The process of claim 9 wherein the blocking polynucleotide consists of antisense.

11. The process of claim 9 wherein the blocking polynucleotide consists of siRNA.

12. The process of claim 1 wherein the hepatic vessel consists of a hepatic vein.

13. The process of claim 1 wherein the hepatic vessel consists of a hepatic artery.

14. The process of claim 1 wherein the hepatic vessel consists of a portal vein.

15. The process of claim 1 wherein the hepatic vessel consists of a bile duct.

Assignments (4)
CHANGE OF NAME Recorded Feb 26, 2014
From: ROCHE MADISON INC.
To: ARROWHEAD MADISON INC.
Reel/Frame 032302/0843 →
CHANGE OF NAME Recorded Feb 24, 2014
From: ROCHE MADISON INC.
To: ARROWHEAD MADISON INC.
Reel/Frame 032282/0694 →
CHANGE OF NAME Recorded Apr 6, 2009
From: MIRUS BIO CORPORATION
To: ROCHE MADISON INC.
Reel/Frame 022629/0791 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2007
From: WOLFF, JON A.; HAGSTROM, JAMES E.; HEGGE, JULIA; BUDKER, TATYANA FOR VLADIMIR BUDKER
To: MIRUS BIO CORPORATION
Reel/Frame 018913/0937 →